Asia Pacific to record the fastest growth.
The global radiotherapy market is projected to grow from $7.98b in 2026 to $10.68b by 2031, according to MarketsandMarkets™.
Growth is being driven by increasing cancer incidence, rising demand for cost-effective treatment, and wider adoption of external beam radiation therapy (EBRT), especially in emerging markets.
Higher healthcare spending, improved reimbursement policies, and expanding investment in oncology infrastructure are also supporting market expansion.
According to the World Bank, global healthcare spending is expected to grow 5–6% annually through 2030, fuelled by demand for advanced technologies such as linear accelerators, proton therapy, and particle therapy.
Emerging economies including Brazil, India, and South Africa are projected to see healthcare investments rise by more than 7% annually.
The system segment—including treatment systems, consumables, probes, and applicators—is expected to record strong growth from 2024 to 2030, driven by increased adoption of radiotherapy in emerging economies and the availability of advanced equipment.
Additionally, external beam radiotherapy (EBRT) is expected to hold the largest market share over the forecast period due to its broad clinical use and rising demand across major markets such as the US, Europe, China, India, and the Middle East.
Asia Pacific is expected to register the highest CAGR, supported by growing cancer prevalence, improving healthcare infrastructure, government support, and rising medical tourism.